TNGX
Tango Therapeutics Inc
NASDAQ: TNGX · HEALTHCARE · BIOTECHNOLOGY
$27.97
-13.38% today
Updated 2026-06-18
Market cap
$5.04B
P/E ratio
—
P/S ratio
88.39x
EPS (TTM)
$-0.83
Dividend yield
—
52W range
$5 – $33
Volume
2.9M
Tango Therapeutics Inc (TNGX) Financial Forecast & Price Target 2030
Research-backed projections from analyst consensus, management guidance, and sector analysis.
Research-backed TNGX price target 2030 projection accounting for share dilution, balance sheet debt, and time value of money.
Current price
$27.97
Today
Analyst consensus
$32.27
+15.37% · 12M
2030 Base
$47.71
+70.58% future
NPV today
$29.25
@ 11% WACC
14 analysts:
10 Buy3 Hold1 Sell
Management guidance
Management has not provided specific quantitative revenue targets through 2030. CEO Malte Peters (appointed Jan 2026) has emphasized advancing vopimetostat toward pivotal trials in pancreatic cancer with initial combination data expected in 2026. Company guided to $380M cash runway into 2028, implying expected cash burn of ~$150-180M annually. No explicit revenue guidance disclosed; focus is on clinical milestones rather than revenue forecasts.
Sources: Management guidance, analyst consensus, sector analysishigh confidence
TNGX · Tango Therapeutics Inc · Revenue & price projection · 2023–2030E
Actual / 2030 target Projected revenue Base case price Bull to bear range
Bear case (2030)
$22.76
NPV today: $13.95
Base case (2030)
$47.71
NPV today: $29.25
Bull case (2030)
$97.62
NPV today: $59.84
WallStSmart.com
TNGX financial forecast · Research-backed projections
| Metric | 2025 | 2026 (E) | 2027 (E) | 2028 (E) | 2029 (E) | 2030 (E) ★ |
|---|---|---|---|---|---|---|
| Revenue | $0.1B | $0.0B | $0.1B | $0.1B | $0.2B | $0.3B |
| Revenue growth | 48.3% | -28.0% | 38.0% | 53.0% | 74.0% | 73.0% |
| Net margin | — | -435.8% | -271.0% | -126.9% | -31.3% | 14.6% |
| EPS | $-1.14 | $-1.35 | $-1.15 | $-0.82 | $-0.35 | $0.28 |
| Diluted shares | — | 145M | 146M | 147M | 148M | 148M |
| Net debt | — | $22.50M | $53.50M | $101.00M | $183.50M | $326.00M |
| P/S multiple | — | 26.0x | 26.0x | 26.0x | 26.0x | 26.0x |
| Implied price (base) | — | $7.90 | $10.67 | $16.12 | $27.80 | $47.71 |
★ 2030E is the model's terminal target year. Implied price = (Revenue × P/S − Net debt) ÷ Diluted shares.
Scenario detail · Three drivers, three outcomes
| 2030E driver | Bear | Base | Bull |
|---|---|---|---|
| Revenue | $0.3B | $0.3B | $0.3B |
| P/S multiple | 13.0x | 26.0x | 52.0x |
| Diluted shares | 148M | 148M | 148M |
| Net debt | $326.00M | $326.00M | $326.00M |
| Implied P/E † | 81x | 170x | 349x |
| 2030 Price | $22.76 | $47.71 | $97.62 |
| NPV @ 11% | $13.95 | $29.25 | $59.84 |
† Implied P/E: Multiples remain elevated across all three scenarios because TNGX is valued primarily on revenue scale during its growth phase, not near-term earnings power. Lower P/E in the bear case reflects multiple compression, but the absolute level stays high since 2030E still represents a hypergrowth-to-mature transition year.
EV to per-share bridge · How we get to $47.71 base case
TNGX catalysts and risks
Growth catalysts
+ Vopimetostat pivotal trial data in pancreatic cancer (2026-2027) — potential accelerated approval pathway
+ PRMT5/RAS(ON) combination trial data readout — demonstrates synergy rationale for clinical advancement
+ TNG456 glioblastoma program advancement — additional oncology indication de-risking
+ Potential partnership/co-development deals leveraging pipeline assets
+ FDA breakthrough designation or fast-track status for vopimetostat combinations
Key risks
- Loss of Gilead collaboration revenue (ended Q1 2026) — eliminated meaningful near-term revenue stream; company now fully R&D-stage
- Clinical trial failure risk — vopimetostat efficacy/safety in pancreatic cancer has not been proven in pivotal trials; regulatory path uncertain
- Cash runway into 2028 is tight — if pivotal trials are delayed or fail, company will require equity financing at potentially lower valuation, causing dilution
- Early-stage pipeline — TNG456, TNG260, TNG348, TNG462 are all pre-pivotal; no near-term revenue catalysts from these programs
- Unprofitable trajectory — company burned $45.5M in Q1 2026 alone; path to profitability requires successful commercialization (post-2028 earliest)
- Competitive oncology landscape — PRMT5 inhibitors and RAS-targeted therapies have multiple players in development
Methodology · Tango Therapeutics Inc 2030 stock forecast model
Tango Therapeutics Inc 2030 price target is calculated using WallStSmart's research model. Revenue projections are derived from analyst consensus across 14 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts. The model is built on five core components:
| 1. Share dilution | Projected from per-ticker schedule of SBC + equity raise activity, compounding year by year (-9% cumulative for TNGX by 2030) |
| 2. Net debt | EV minus net debt yields equity value; debt projected from capex cycle trajectory ($326.00M by 2030) |
| 3. Time value | NPV calculated using 11% WACC (CAPM: beta 1.223) |
| 4. Multiple framework | P/S compresses with scale: bear 13.0x / base 26.0x / bull 52.0x |
| 5. Scenario design | Bull/Base/Bear vary revenue, margin, shares, debt, and multiple independently |
WallStSmart research model · Not financial advice · Past performance is not indicative of future results · Last researched: May 20, 2026.
TNGX price target FAQ
What is the TNGX price target for 2030?
WallStSmart's Tango Therapeutics Inc 2030 base case is $47.71 per share, with a bull case of $97.62 and bear case of $22.76. The NPV of the base case discounted to today at 11% WACC is $29.25.
How is the Tango Therapeutics Inc 2030 stock forecast calculated?
The TNGX 2030 projection multiplies projected revenue by a growth-adjusted P/S multiple to derive enterprise value, subtracts projected net debt to get equity value, then divides by diluted shares outstanding accounting for dilution from stock-based compensation and equity raises.
Why does the TNGX price target account for dilution?
Tango Therapeutics Inc is projected to grow diluted share count from 163M to 148M by 2030 (a -9% increase) through stock-based compensation and capital raises. Ignoring this would inflate the price target by approximately -9%.
What is the analyst consensus on TNGX stock?
14 analysts cover TNGX with an average 12-month price target of $32.27. The 2030 projection extends this framework with longer-horizon assumptions including dilution and time value of money.